Utilization of antiobesity medications within the Military Health System
Authors' conclusion
Comparable with the US private sector, the MHS significantly underutilizes AOMs, including among active-duty service members, despite coverage of AOMs since 2018.
Study context
- Population
- Adult TRICARE Prime and Plus beneficiaries aged 18–64 years in the Military Health System (MHS), 2018–20221,871,780 active duty
- Participants
- 4,414,127 participants
- Outcome
- Utilization of antiobesity medications (AOMs) within the MHS
Methodological detailsData from the MHS Data Repository
- Data from the MHS Data Repository
Main finding
As reported in the abstract
AOM utilization
AOM utilization among eligible population
0.56%
AOM utilization among active-duty personnel
0.44%
Observational data: associations, not effects.
Further findings
Most-prescribed AOM
- Liraglutide, share of total
- 36%
Factors associated with receiving antiobesity medications (AOMs)
- Female sex, age ≥30 but <60 years, and enlisted or warrant officer rank associated with statistically significant higher odds of receiving AOMs
Original publication
Utilization of antiobesity medications within the Military Health System. Obesity (Silver Spring). Published 1 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →